Aviara H/ISM Publications and Scientific Presentations
Publications
A Five-GeneMolecular Grade Index and HOXB13:IL17BR
Are Complementary Prognostic Factors in Early Stage
Breast Cancer.
Clinical Cancer Research, May 1, 2008
The Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer. Wang et al. Clinical Cancer Research. November 1, 2007 13(21):6327-6334.
Exploring the Two-Gene Ratio in Breast Cancer - Independent Roles for HOXB13 and IL17BR in Prediction of Clinical Outcome. Jerevall et al. Breast Cancer Research Treatment. April 24, 2007 online publication
HOXB13-to-IL17BR Expression Ratio is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. Jansen M.P.H.M., et al. Journal of Clinical Oncology. February 2007 25(6):662-668.
The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer. Ma X, et al. Journal of Clinical Oncology. October 2006 24(28):4611-4619.
A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen. Goetz, Matthew P, et al. Clinical Cancer Research. April 2006 12: 2080-2087.
A Two-Gene Expression Ratio Predicts Clinical Outcome in Breast cancer Patients Treated with Tamoxifen. Ma X, et al. Cancer Cell 2004 5:607-616.
Scientific Presentations:
ASCO Poster, September 2007
Molecular Grade Index (MGI) and H:I Ratio are Complementary Prognostic Factors in Breast Cancer
American Association for Cancer Research, 2007
HOXB13 to IL17BR Gene Expression Ratio is Not Associated with Tumor Infiltrating Lymphocytes in Estrogen Positive, Node Negative Breast Cancer
San Antonio Breast Cancer Symposium, December 2005: The HOXB13:IL17BR Index is a Prognostic Factor in Early Stage Breast Cancer
San Antonio Breast Cancer Symposium, December 2005: A Two-gene Expression Ratio of HOXB13 and IL-17BR for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
| TOP |
|
